87.82
Precedente Chiudi:
$100.96
Aprire:
$102.52
Volume 24 ore:
161.56K
Relative Volume:
3.13
Capitalizzazione di mercato:
$541.85M
Reddito:
-
Utile/perdita netta:
$-7.12M
Rapporto P/E:
-38.18
EPS:
-2.3
Flusso di cassa netto:
$-6.82M
1 W Prestazione:
-11.64%
1M Prestazione:
+104.71%
6M Prestazione:
+175.56%
1 anno Prestazione:
+1,599%
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Confronta MNPR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MNPR
Monopar Therapeutics Inc
|
87.82 | 622.92M | 0 | -7.12M | -6.82M | -2.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-09-09 | Iniziato | BTIG Research | Buy |
2025-09-03 | Iniziato | Oppenheimer | Outperform |
2025-09-03 | Iniziato | Raymond James | Strong Buy |
2025-08-26 | Ripresa | H.C. Wainwright | Buy |
2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
2025-06-23 | Iniziato | Chardan Capital Markets | Buy |
2025-03-19 | Ripresa | Piper Sandler | Overweight |
2025-01-10 | Iniziato | Piper Sandler | Overweight |
2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
2021-01-28 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
Real time social sentiment graph for Monopar Therapeutics Inc.Weekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Raised to Strong-Buy at Jones Trading - Defense World
Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 12.3%Here's What Happened - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Upgraded to "Strong-Buy" at Jones Trading - MarketBeat
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted (NASDAQ:MNPR) - Seeking Alpha
Institutional scanner results for Monopar Therapeutics Inc.2025 Momentum Check & High Win Rate Trade Alerts - newser.com
Monopar Therapeutics' (MNPR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential - TipRanks
What analysts say about Monopar Therapeutics Inc stockProtective Put Strategies & Low Risk Investment Trading - earlytimes.in
How Monopar Therapeutics Inc. (1IY0) stock reacts to monetary easingJuly 2025 Breakouts & Precise Trade Entry Recommendations - newser.com
Raymond James Maintains Monopar Therapeutics (MNPR) Strong Buy Recommendation - Nasdaq
MNPR: Raymond James Raises Price Target to $142, Maintains Stron - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Hits New 1-Year HighTime to Buy? - MarketBeat
How to integrate Monopar Therapeutics Inc. into portfolio analysis toolsWatch List & Fast Gaining Stock Strategy Reports - newser.com
Historical volatility pattern of Monopar Therapeutics Inc. visualizedTrade Entry Summary & Entry Point Strategy Guides - newser.com
Will Monopar Therapeutics Inc. (1IY0) stock beat Nasdaq index returnsTrade Risk Summary & Long-Term Safe Investment Ideas - newser.com
Will Monopar Therapeutics Inc. stock recover faster than peersMarket Performance Report & Weekly Hot Stock Watchlists - newser.com
Risk adjusted return profile for Monopar Therapeutics Inc. analyzedJuly 2025 Big Picture & High Return Stock Watch Alerts - newser.com
Can trapped investors hope for a rebound in Monopar Therapeutics Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Is Monopar Therapeutics Inc. (1IY0) stock overpriced at current multiplesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
Is Monopar Therapeutics Inc. stock safe for conservative investorsPortfolio Gains Summary & Safe Entry Zone Identification - newser.com
Using portfolio simulators with Monopar Therapeutics Inc. includedJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Analyzing Monopar Therapeutics Inc. with risk reward ratio chartsGlobal Markets & Community Shared Stock Ideas - newser.com
Can volume confirm reversal in Monopar Therapeutics Inc.July 2025 Macro Moves & Reliable Price Breakout Signals - newser.com
Oppenheimer Maintains Monopar Therapeutics (MNPR) Outperform Recommendation - Nasdaq
Oppenheimer Raises Price Target for Monopar Therapeutics (MNPR) - GuruFocus
Oppenheimer Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $115 - 富途牛牛
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $104 - 富途牛牛
HC Wainwright Has Optimistic Outlook of MNPR FY2027 Earnings - Defense World
What is HC Wainwright's Estimate for MNPR FY2027 Earnings? - MarketBeat
What analysts say about Ayro Inc stockStop Loss Placement Tips & Exceptional Return Opportunities - earlytimes.in
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Monopar Therapeutics Inc Azioni (MNPR) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Tsuchimoto Kim R | Director |
Jul 14 '25 |
Sale |
40.00 |
8,904 |
356,171 |
11,486 |
STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):